Slide 1: Investor Presentation – AngelMed Guardian FDA Approval
ASX Announcement 30/06/2021 Investor Presentation – AngelMed Guardian FDA Approval Hydrix Limited (ASX: HYD) attaches an investor presentation in relation to the recent FDA approval of the AngelMed Guardian device, as announced to the market on 28 June 2021. A recorded presentation given by Executiv
Slide 2: Hydrix Limited
Hydrix Limited Hydrix brings technologies to life which improve people’s health, safety and well-being AngelMed FDA Approval ASX Announcement on 28 June
Slide 3: MedTech/Cardiac business poised for strong product revenue growth
MedTech/Cardiac business poised for strong product revenue growth ▪ Diversified medtech product design services and distribution business – 18-year history, global customers ▪ “One stop Services shop” bringing medical technology concepts to commercialisation ▪ Exclusive APAC rights to distribute wor
Slide 4: Hydrix Medical – Portfolio overview
Hydrix Medical – Portfolio overview AngelMed Guardian Phyzhon A 3% A 15% capture rate capture rate of patient of PCI market = surgery $100m rev market = p.a. (15k $25m rev p.a. units) (20k units) Implanted Heart Monitor Interventional cardiology device • 3rd party distribution agreement (7 years +2
Slide 5: Indicative Milestone Timelines / Potential News Flow
Indicative Milestone Timelines / Potential News Flow 1H FY22 2H FY22 ▪ Submit TGA (AUS) and HSA (SNG) regulatory ▪ AngelMed Guardian TGA (AUS) & HSA (SNG) approval for AngelMed Guardian regulatory approval ▪ First implants of AngelMed Guardian in ▪ AngelMed Guardian AUS health reimbursement Australi
Slide 6: Disclaimer
Disclaimer This presentation has been prepared by Hydrix Limited (the “Company” or “Hydrix”). This presentation is being provided to investors for the sole purpose of providing preliminary background financial and other information to enable recipients to review the business activities of the Compan